A Cochrane meta-analysis noted that all major treatment classes reviewed were more effective than placebo for moderate to severe psoriasis; however, biologic agents appeared to be the most efficacious. Evaluation of data from 109 studies revealed that anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha drugs were superior for achieving PASI 90 status (90% reduction in Psoriasis Area and Severity Index score). All of the anti-IL17 drugs and guselkumab were found to be more effective than the anti-TNF alpha drugs infliximab, adalimumab, and etanercept for attaining PASI 90 status. Ustekinumab, an IL-12/23 inhibitor, was better than etanercept. Tofacitinib was superior to methotrexate. The findings are published online in Cochrane Library.